Cardiovascular history, abiraterone acetate, and 6-month mortality rates

In a not entirely surprising set of findings, data from a relatively large registry study — to be presented at an upcoming meeting of the American Association of Cancer Research (AACR) — suggest that treatment with abiraterone acetate raises risk for cardiovascular-related mortality among prostate cancer patients with known cardiovascular risk factors. … READ MORE …

ADT and cardiovascular side effects — redux

A few days ago we commented briefly on a paper by Haque et al. on the risk for cardiovascular complications and side effects of ADT in men initially diagnosed with localized prostate cancer and supposedly managed, initially, on active surveillance. … READ MORE …

ADT and risk for cardiovascular complications of therapy

Not so long ago, we addressed the question of whether first-line androgen deprivation therapy (ADT) was really an appropriate form of care for any man with localized prostate cancer. … READ MORE …

Are LHRH antagonists more appropriate for some patients than LHRH agonists?

A new paper from a panel of experts in the UK has suggested that the use of LHRH antagonists (e.g., degarelix) may be more appropriate than the use of LHRH agonists (e.g., leuprolide acetate of goserelin acetate) in some prostate cancer patients. … READ MORE …

Lowering risk of death from prostate cancer AND cardiovascular disease

Based on a specific case study, a new paper in Circulation by a group of clinicians at Vanderbilt University Medical Center describes their program designed to reduce risk of death from cardiovascular disease for prostate cancer patients on androgen deprivation therapy (ADT). … READ MORE …

Prostate cancer, cardiovascular disease, and the role of ADT

A new trial to be discussed at the Genitourinary Cancers Symposium is the RADICAL-PC trial, designed to give us a greater understanding of the roles of androgen deprivation (ADT) and other factors in causing cardiovascular disease in high-risk prostate cancer patients. … READ MORE …

Adding ADT to radiation therapy may carry increased cardiovascular risk

Some recent randomized clinical trials have shown that adding androgen deprivation therapy (ADT) to radiation therapy can improve outcomes in some circumstances. However, … READ MORE …